Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists (Q40489026)

21 September 2017

1 reference

title

Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists (English)

1 reference

21 September 2017

main subject

prostatic hypertrophy

1 reference

J M Monda

1

1 reference

21 September 2017

J E Oesterling

series ordinal

2

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 July 1993

1 reference

21 September 2017

1 reference

21 September 2017

volume

68

1 reference

21 September 2017

issue

7

1 reference

21 September 2017

page(s)

670-679

1 reference

The development of human benign prostatic hyperplasia with age

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Controversies about indications for transurethral resection of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Transurethral prostatectomy: practice aspects of the dominant operation in American urology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Symptom status and quality of life following prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Androgen- and Estrogen-Receptor Content in Spontaneous and Experimentally Induced Canine Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

The clinical development of a 5α-reductase inhibitor, finasteride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Effect of a new 5 alpha-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

5 Alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Pharmacological receptors in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Alpha 1 adrenergic receptors in canine lower genitourinary tissues: insight into development and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Effects of Prazosin in Patients with Benign Prostatic Obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

A Multicenter, Double-Blind, Placebo-Controlled Trial of the Efficacy of Prazosin in the Treatment of Dysuria Associated with Benign Prostatic Hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

Light Microscopic Stereological Analysis of the Normal Human Prostate and of Benign Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

7 January 2021

Etiology and disease process of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

7 January 2021

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

7 January 2021

Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960603-X

7 January 2021

10.1016/S0025-6196(12)60603-X

Identifiers

DOI

1 reference

21 September 2017

1 reference